But going first, thats a big bet to build the production capacity to be able to sustain a market thats going to go from zero to tens of billions of dollars pretty rapidly. For companies with up-and-coming GLP-1s, there is likely to be a greater motivation around the middle phase of development to take a little more risk in upfront investment in manufacturing because theres already a scientifically proven hypothesis out in the marketplace, he said.
While medical weight loss is not a cure for these conditions, achieving and maintaining a healthier weight may become an important part of an overall healthcare plan developed with your physician
They are not licensed for human use in the UK and carry risks including fluid retention, insulin resistance, and joint discomfort
In 2024, the ESC guidelines for elevated blood pressure and hypertension classified GLP-1 RA as therapies that have shown blood pressure-lowering properties but are awaiting further supportive evidence from cardiovascular outcomes trials prior to guideline endorsement and routine use in hypertension [49]
The pattern is usually obvious in retrospect
X.WangM
